Uses
Potassium Chloride in Dextrose Injection is indicated as a source of water, electrolytes and calories.
Source: US FDA prescribing information
Fixed-dose combination
Dextrose and Potassium chloride is a fixed-dose combination of an osmotic laxative and a potassium salt indicated as a source of water, electrolytes and calories. It is available as injection for intravenous use. MedsAcross supplies Dextrose and Potassium chloride for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Potassium Chloride in Dextrose Injection is indicated as a source of water, electrolytes and calories.
Source: US FDA prescribing information
Potassium Chloride in Dextrose Injection is a source of water, electrolytes and calories. It is capable of inducing diuresis depending on the clinical condition of the patient.
Source: US FDA prescribing information
• Only for intravenous infusion. • See full prescribing information for information on preparation, administration, dosing considerations and instructions for use.
Source: US FDA prescribing information
Potassium Chloride in Dextrose Injection is contraindicated in patients with: • known hypersensitivity to potassium chloride and/or dextrose • clinically significant hyperkalemia • clinically significant hyperglycemia • Known hypersensitivity to potassium chloride or dextrose. • Clinically significant hyperkalemia. • Clinically significant hyperglycemia
Source: US FDA prescribing information
• Hypersensitivity Reactions: monitor for signs and symptoms and discontinue infusion if reactions occur. • Hyperkalemia: May result in cardiac arrhythmias. Avoid use in patients with, or at risk for, hyperkalemia. If use cannot be avoided, use a product with a low amount of potassium chloride, infuse slowly and monitor serum potassium concentrations and ECGs. • Hyperglycemia or Hyperosmolar Hyperglycemic State: Monitor blood glucose and administer insulin as needed. • Hyponatremia: Avoid in patients with or at risk for hyponatremia. If use cannot be avoided, monitor serum sodium concentrations. • Hypokalemia: Avoid in patients with or at risk for hypokalemia. If use cannot be avoided, monitor serum potassium levels. • Fluid Overload: Avoid in patients with or at risk for fluid and/or solute overloading.
Source: US FDA prescribing information
The following adverse reactions associated with the use of Potassium Chloride in Dextrose Injection were identified in post marketing reports. Because these reactions were reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The following clinically significant adverse reactions are described elsewhere in the labeling: • Hypersensitivity reactions: including anaphylaxis and chills.
Source: US FDA prescribing information
• Other Products that Cause Hyperkalemia: Avoid use in patients receiving such products. If use cannot be avoided, monitor serum potassium concentrations. • Other Products that Affect Glycemic Control, Vasopressin or Fluid and/or Electrolyte Balance: Monitor blood glucose concentrations, fluid balance serum electrolyte concentrations and acid-base balance.
Source: US FDA prescribing information
Store at room temperature (25°C), brief exposure up to 40°C does not adversely affect the product.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Dextrose and Potassium chloride, sorted by availability.
| Medicine | Active ingredient | Manufacturer | Register | Availability |
|---|---|---|---|---|
| Dextrose and Potassium chloride 50 g/1500 mg per 1000 mL injectionIntravenousGeneric name | Dextrose and Potassium chloride | — | US FDA | Available on request |
| Dextrose and Potassium chloride 50 g/1.49 g per 1000 mL injectionIntravenousGeneric name | Dextrose and Potassium chloride | — | US FDA | Available on request |
| Dextrose and Potassium chloride 50 g/750 mg per 1000 mL injectionIntravenousGeneric name | Dextrose and Potassium chloride | — | US FDA | Available on request |
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 1 February 1979 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 3 presentations of Dextrose and Potassium chloride and sources them for licensed hospitals, importers and physicians against valid import documents.
Yes. The US FDA first approved Dextrose and Potassium chloride on 1 February 1979, according to Drugs@FDA.
No listed presentation of Dextrose and Potassium chloride is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.